GFP Adeno-Associated Virus ( AAV-DLGSARA )

In gene therapy, in vivo vector targeting is critical. For adeno-associated viruses (AAV), this problem has been addressed by inserting peptide ligands into the vector capsid or exploiting the diversity of various capsid serotypes. Despite great progress in this field, there are very limited tissue-targeted vectors available for in vivo use, especially when administered intravenously. Screening of random AAV display peptide libraries is an innovative tool that can be used to select vectors that effectively transduce any cell type of interest, and a variety of cell types have been described and validated in vitro. At the core of AAV-DLGSARA is adeno-associated virus serotype 2 (AAV2). AAV2 is a well-characterized and commonly used serotype known for its relatively benign nature and ability to infect both dividing and non-dividing cells, making it an ideal candidate for a variety of therapeutic applications. For AAV-DLGSARA, the capsid was modified by inserting the peptide sequence DLGSARA at position I588 of the viral capsid protein. This strategic insertion confers better properties to the virus, allowing it to target specific cell types, such as tumor cells.